Page 2465 - Williams Hematology ( PDFDrive )

2436 Index Index 2437

Gelatinous transformation, of marrow, 33 targeted-insertion, 443–444, 443f GIG2. See CD9
Gelfoam, 2062 for thalassemias, 753 Gilbert syndrome, 565
Gelsolin, 1832t, 1840 T lymphocytes in, 438 Gil blood group, 2332t
Gemcitabine, 322 vectors for, 438–439 Gingival bleeding, 5, 8, 1987
adverse effects, 2263 for Wiskott-Aldrich syndrome, 439 Ginkgo biloba, 1986
for Hodgkin lymphoma, 1616 for X-linked severe combined Ginseng, 1986
for mantle cell lymphoma, 1659t immunodeficiency, 437, 439, 453, Givinostat, for polycythemia vera, 1300
Gemtuzumab ozogamicin 1219 Gla (γ-carboxyl glutamic acid) domain,
for acute myelogenous leukemia, 271, Genetic Information Nondiscrimination Act 1915–1918, 1917f, 1918f, 1919f
1395t, 1396, 1402t, 1403 (GINA), 162 Glanzmann thrombasthenia (GT), 2042–2047
ATRA and, 1404 Genetics. See also specific diseases clinical features, 1985, 2046, 2046t
removal from market, 346, 1403 aging and, 130 definition and history, 2042–2043
Gender autosomal dominant inheritance, 148, 148f etiology and pathogenesis, 1842, 1865,
acute lymphoblastic leukemia and, 1506, autosomal recessive inheritance, 149, 149f 1995, 2043–2046, 2043f, 2044f,
1506f chromosomal abnormalities. See 2359
acute lymphoblastic leukemia prognosis Chromosomal abnormalities laboratory features, 2046–2047, 2046t
and, 1520 expressivity, 149 therapy, course, and prognosis, 2047, 2062
hairy cell leukemia and, 1554 linkage analysis, 151–152, 151f Gliomas, 170
hemophilia A and, 2116 Mendelian, 147 Gln506-factor V. See Factor V Leiden/factor V
lymphoma and, 1570, 1570f mutations. See Gene mutations G1691A
myelodysplastic syndromes and, 1345 penetrance, 149 GLOB blood group, 2332t, 2334t, 2337, 2344t
primary myelofibrosis and, 1319 X inactivation, 150, 150f Globin chains, 728, 740, 781
Gene duplication, 147–148 X-linked inheritance, 149–151 Globin gene clusters, 728–730, 729f
Gene editing, 443–444 Genitourinary system Globin synthesis, disorders of. See
Gene expression blood loss from, 629 Thalassemias
interference with, 153 complications in sickle cell disease, Globoside, 2340
macrophage, 1064–1066 770–771 Gloves-and-socks syndrome, 2104
regulation, 165–166 history of disorders of, 5–6 Glucocerebrosidase, 1121, 1122, 1122f
Gene mutations, 146. See also individual primary lymphomas in, 1581–1582 Glucocorticoids
genes; specific diseases Genome, 145 for acute lymphoblastic leukemia, 1515,
in major lymphoid malignancies, 231–237t Genome-wide association studies (GWAS), 1516, 1517
in major myeloid malignancies, 226–230t 162 for antiphospholipid syndrome in
next-generation sequencing analysis, Genomics pregnancy, 2245
160–161 history, 155 for aplastic anemia, 526
Gene repair, 453 next-generation sequencing. See Next- for autoimmune hemolytic anemia, 838,
Gene therapy, 437–444 generation sequencing 840, 1541
for adenosine deaminase deficiency severe Genotype-phenotype correlations, 146 for chronic lymphocytic leukemia,
combined immunodeficiency, 439 Gentamicin, 387t 1536–1537
for brain tumors, 442 Geranylgeranyltransferase-1 inhibitors, 1403 for Diamond-Blackfan anemia, 540
for chronic granulomatous disease, 1032 Gerbich blood group, 2332t, 2337, 2346t eosinophilic granulomatosis with angiitis,
for chronic lymphocytic leukemia, 442 Gerbich-negative phenotype, 2342–2343 960
definition and history, 437 Germ cell tumors, mediastinal, 1386–1387 for Erdheim-Chester disease, 1111
for Diamond-Blackfan anemia, 540 Germinal center, lymph node, 1589, 1590f erythropoietin and, 560
ex vivo, 437, 438f Germinal center B-cell-like diffuse large excess, 2107–2108
for Fanconi anemia, 442 B-cell lymphoma, 234–235t, 1495t, for hypereosinophilic syndrome, 959
for Glanzmann thrombasthenia, 2062 1626, 1627t for immune thrombocytopenia, 2003–
graft-versus-host disease prevention in, Germline mosaicism, 148 2004
440, 440f Gestational thrombocytopenia, 45, 121–122, for lymphomatoid papulosis, 1689
hematopoietic stem cells in, 437 2010 macrophage deactivation and, 1070t
for hemophilia, 2129–2130 GFI1B, 2061 for mastocytosis, 977
for HIV infection, 440–441, 454, 1243 GH (growth hormone), 561, 1407 for mononucleosis, 1269
in vivo, 437, 438f Giant cell reticulosis, 1109 for mycosis fungoides, 1685
for leukodystrophies, 439 Giant cell tumor of the bone, 1110 for neonatal alloimmune
MGMT selective method, 442, 443f Giant follicular lymphoma, 1569 thrombocytopenia, 2013
principles, 153, 437, 438f, 453–454 Giant metamyelocyte, 593 neutrophilia and, 1001
for sickle cell disease, 453 Giardia lamblia, 1212, 1216 neutrophil motility and, 1026

Kaushansky_index_p2393-2506.indd 2436 9/21/15 3:22 PM